2023
Percutaneous Ablation, Osteoplasty, Reinforcement, and Internal Fixation for Pain and Ambulatory Function in Periacetabular Osteolytic Malignancies.
Dussik C, Toombs C, Alder K, Yu K, Berson E, Ibe I, Li F, Lindskog D, Friedlaender G, Latich I, Lee F. Percutaneous Ablation, Osteoplasty, Reinforcement, and Internal Fixation for Pain and Ambulatory Function in Periacetabular Osteolytic Malignancies. Radiology 2023, 307: e221401. PMID: 36916888, DOI: 10.1148/radiol.221401.Peer-Reviewed Original ResearchConceptsOsteolytic neoplasmAmbulatory functionInternal fixationEastern Cooperative Oncology Group scoreIndex scoreConversion hip arthroplastyRetrospective observational studySurgical site infectionKaplan-Meier analysisLong-term painQuality of lifeLong-term improvementWilcoxon signed-rank testNonambulatory patientsSecondary outcomesPrimary outcomeSite infectionOncologic careECOG scorePercutaneous ablationPeriacetabular metastasisProtrusio acetabuliFunctional improvementSigned-rank testClinical dataEmerging Minimally Invasive Percutaneous Procedures for Periacetabular Osteolytic Metastases
Ibe I, Dussik C, Callan A, Barr J, Lee F. Emerging Minimally Invasive Percutaneous Procedures for Periacetabular Osteolytic Metastases. Journal Of Bone And Joint Surgery 2023, 105: 479-489. PMID: 36701566, DOI: 10.2106/jbjs.22.00694.Peer-Reviewed Original ResearchConceptsInvasive percutaneous proceduresOsteolytic metastasesInvasive proceduresPercutaneous proceduresCancer ablationOsteolytic skeletal metastasesOpen surgical managementPercutaneous screw fixationSystemic cancer therapyOpen surgical proceduresRestoration of ambulationComplex open surgical proceduresPeriacetabular osteolytic lesionsBalloon osteoplastyAmbulatory functionTotal hip reconstructionBlood lossOsteolytic lesionsSkeletal metastasesSurgical managementInterventional oncologistsInternal fixationSurgical proceduresInvasive techniquesScrew fixation
2021
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
Briot K, Portale AA, Brandi ML, Carpenter TO, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Ing S, Insogna K, Ito N, de Beur S, Javaid MK, Kamenicky P, Keen R, Kubota T, Lachmann RH, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Nixon A, Nixon M, Sun W, Williams A, Imel EA. Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open 2021, 7: e001714. PMID: 34548383, PMCID: PMC8458321, DOI: 10.1136/rmdopen-2021-001714.Peer-Reviewed Original ResearchConceptsBrief Pain Inventory-Short FormPatient-reported outcomesBrief Fatigue InventoryBPI-SF scoresAmbulatory functionWeek 96Burosumab treatmentMcMaster Universities Osteoarthritis IndexOpen-label extensionDouble-blinded trialPhase 3 trialMin walk testSignificant improvementWOMAC stiffnessOsteoarthritis IndexWeek 48Worse fatigueWeek 24Walk testFatigue InventoryWestern OntarioBFI scoresSubstantial burdenWOMACBurosumab
2014
Thoracic Epidural Teratoma: Case Report and Review of the Literature
Quon JL, Grant RA, Huttner AJ, Duncan CC. Thoracic Epidural Teratoma: Case Report and Review of the Literature. Sage Open Pathology 2014, 7: cpath.s14723. PMID: 24940089, PMCID: PMC4055415, DOI: 10.4137/cpath.s14723.Peer-Reviewed Original ResearchSpinal teratomaClinical presentationSevere spinal cord compressionDiagnosis of teratomaSpinal cord compressionGross total resectionSpinal cord tumorsHeterogeneous contrast enhancementSignificant neurologic compromiseClinician's differentialMarked spasticityAmbulatory functionCord compressionCord tumorsTotal resectionNeurologic compromiseEpidural tumorCystic massRare entityCase reportRare subsetMotor milestonesTumorsTeratomaPathophysiology
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply